ArticleJournal of virology2025
Comparison of the biological properties of bat-derived filovirus envelope glycoproteins.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Although some filoviruses, such as Ebola virus (EBOV) and Marburg virus (MARV), are highly pathogenic in humans, novel filoviruses, including Lloviu virus (LLOV), Bombali virus (BOMV), Mengla virus (MLAV), and Dehong virus (DEHV), whose biological properties are poorly understood, have been found in bats. In this study, we characterized the envelope glycoproteins (GPs) of these bat-derived filoviruses (BatFiloVs). We first confirmed that virus-like particles consisting of their GPs, nucleoproteins, and matrix proteins were filamentous. Interestingly, although BatFiloVs were serologically distinct, some previously established monoclonal antibodies (MAbs) (e.g., 6D6) successfully neutralized vesicular stomatitis Indiana viruses pseudotyped with LLOV, BOMV, or DEHV GPs. The pseudotyped viruses bearing BatFiloV GPs utilized human TIM-1 and C-type lectins for entry into cells, although the efficiency tended to be lower than for EBOV and/or MARV GP-pseudotyped viruses. These viruses broadly infected cultured cells derived from various animal species, including humans and bats. However, viruses pseudotyped with DEHV and MARV GPs failed to infect the Yaeyama flying fox cell line, whereas the other pseudotyped viruses infected this cell line. Interestingly, the virus bearing BOMV GP showed the greatest ability to infect cell lines derived from Angolan free-tailed bats, the only known host species of BOMV. We identified unique amino acid residues at the interface between GP and its receptor (i.e., Niemann-Pick C1), which might explain these differences. Our results suggest that the biological properties of filovirus GPs are generally consistent with their phylogenetic relationship and that BatFiloVs may have differential pathogenicity and host range restriction.IMPORTANCEFiloviruses, such as EBOV and MARV, are known to cause severe hemorrhagic fever in humans and nonhuman primates. With the recent advancements in next-generation sequencing, novel filoviruses have been detected in bats. However, their pathogenicity and host tropism remain largely unknown. Here, we focus on the filovirus spike protein GP, which plays a crucial role in the viral lifecycle, and discuss the biological properties of BatFiloVs. We studied the primary structures of GPs, virus particle morphology, antigenic differences of GPs, neutralizing capacities of anti-EBOV and -MARV GP MAbs, usage of some attachment factors during the entry into cells, and GP-mediated cellular tropism. The present study provides fundamental information for understanding the BatFiloV ecology, host ranges, and potential risks as zoonotic pathogens for humans. This knowledge will guide public health interventions to prevent virus spillovers and the development of surveillance strategies and specific countermeasures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.